Economic evaluation of monoclonal antibody in the management of colorectal cancer in Malaysia
The introduction of monoclonal antibody in the management of Colorectal Cancer (CRC) in the rapidly rising healthcare cost environment prompt a proper evaluation of its cost effectiveness especially to the local setting. The rising incidence of CRC in Malaysia also justifies a detailed evaluation on its economic impact. This study aims to determine the cost of CRC management and to compare the cost effectiveness of monoclonal antibody with conventional chemotherapy in the management of CRC.
This economic evaluation study was performed from the societal perspective. It involves collecting resource utilization data based on clinical pathway of colorectal cancer management. Cost calculated included cost of drugs, human resources, administrative, investigations as well as capital cost. Direct and indirect patient’s cost were also calculated based on interview with CRC patients. CRC patients’ quality of life were measured using EORTC QLQ-C30 questionnaire and effectiveness
- Economic evaluation of monoclonal antibody in the management of colorectal cancer in Malaysia
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
BMC Health Services Research
- Online Date
- November 2012
- Online ISSN
- BioMed Central
- Additional Links
- Author Affiliations
- 1. National University of Malaysia, Cheras, Kuala Lumpur, Malaysia
- 2. United Nations University International Institute for Global Health, Kuala Lumpur, Malaysia